APTUIT (VERONA) SRL

Their core work

Aptuit is a contract research organization (CRO) based in Verona, Italy, specializing in preclinical drug discovery and pharmaceutical development services. Their H2020 participation centers on providing industry-side expertise in drug formulation, pharmacokinetics, and compound screening — particularly for anti-infective and anti-inflammatory therapeutics. They serve as an industrial training host in Marie Skłodowska-Curie networks, offering early-career researchers hands-on experience in pharmaceutical R&D workflows. Their role across projects consistently involves translating academic drug candidates into viable pharmaceutical formulations.

What they specialise in

How they've shifted over time

Aptuit's H2020 involvement is concentrated in a narrow 2015–2017 start window, making temporal evolution hard to assess. Their earliest project (INTEGRATE, 2015) focused on classical antibacterial target validation, while later entries added nanomedicine (FOLSMART, 2016) and personalized medical devices (PRINT-AID, 2017). This suggests a gradual broadening from traditional small-molecule drug discovery toward more advanced delivery platforms and device-drug combinations.

Aptuit moved from conventional drug screening toward advanced delivery systems and personalized therapeutics, suggesting growing interest in formulation-intensive projects rather than pure target discovery.

How they like to work

Aptuit operates exclusively as a participant, never leading consortia — consistent with their CRO business model where they provide specialized services rather than set research agendas. With 33 unique partners across 13 countries from just 3 projects, they engage in large, internationally diverse consortia typical of MSCA training networks. Their role is that of an industry anchor: a company that receives researchers, provides real-world training, and contributes pharmaceutical infrastructure to academic-led projects.

Despite only three projects, Aptuit has built connections with 33 partners across 13 countries, reflecting the broad consortium structure of MSCA training networks. Their network spans Western and Southern Europe with no obvious geographic concentration beyond their Italian base.

What sets them apart

Aptuit brings something rare to EU consortia: a full-scale industrial pharmaceutical development facility willing to host and train academic researchers. Most CROs of this caliber do not participate in training networks, making Aptuit a valuable bridge between academic drug discovery and industrial-grade formulation and testing. For consortium builders, they offer credible industry partnership without the bureaucratic complexity of engaging a major pharma company.

Highlights from their portfolio

• FOLSMART
  Largest single grant (EUR 653K) and their only RIA project, focused on nanotechnology-based drug delivery for rheumatoid arthritis — indicates deeper research contribution beyond training host roles.
• INTEGRATE
  Addresses the critical global health challenge of Gram-negative antibiotic resistance, an area where new antibacterial targets are urgently needed and industry participation is essential for translational success.